At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
ARQ-151 cream 0.3%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 6 to 11 Years Old) With Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating ARQ-151 cream 0.3% for Psoriasis and Plaque Psoriasis. Completed, enrolled 20 participants across 17 sites in 3 countries.
Detailed Summary
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Plaque Psoriasis
CountriesCanada, Dominican Republic, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedDec 2020
Primary CompletionJan 2022
TodayJul 2026
First PostedDec 7, 2020
Enrollment StartNov 30, 2020
Primary CompletionJan 12, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.6 years ago
Interventions
ARQ-151 cream 0.3%drug
ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks